SCHEMBL22715879

SCHEMBL22715879

Cc1ccc(Cl)nc1C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
IKBKB O14920 4/20 0.38
SYK P43405 1/20 0.37
LMNA P02545 2/20 0.36
F2 P00734 1/20 0.36
ALDH1A1 P00352 3/20 0.36
SIRT3 Q9NTG7 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CTSA P10619 1/20 0.36
DGAT1 O75907 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
RRM1 P23921 1/20 0.36
RRM2B Q7LG56 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
PKM P14618 1/20 0.35
ADORA2A P29274 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31559908 1.00 POLB (0.43) POLBIKBKBSYKLMNAF2
SCHEMBL1428059 0.82 ALDH1A1 (0.46) ALDH1A1TDP1MAPK1SMN1; SMN2CTSA
SCHEMBL29439572 0.82 ALDH1A1 (0.46) ALDH1A1TDP1MAPK1SMN1; SMN2CTSA
SCHEMBL20209504 0.82 ALDH1A1 (0.38) IKBKBLMNAALDH1A1MAPK1SMN1; SMN2
SCHEMBL27023247 0.81 KMT2A (0.41) POLBIKBKBSYKLMNAF2
SCHEMBL28078792 0.80 ALDH1A1 (0.44) ALDH1A1TDP1MAPK1SMN1; SMN2CTSA
SCHEMBL31141501 0.79 KMT2A (0.47) IKBKBLMNAF2ALDH1A1CTSA
SCHEMBL2212207 0.79 KMT2A (0.47) IKBKBLMNAF2ALDH1A1CTSA
SCHEMBL29771502 0.79 PARP1 (0.46) POLBIKBKBSYKLMNASIRT3
SCHEMBL18837073 0.79 PARP1 (0.46) POLBIKBKBSYKLMNASIRT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 US disclosed
US-20260076968-A1 AZA-QUINOLINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2026-03-19 US disclosed
EP-4034535-B1 AZA-QUINOLINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2026-03-04 EP disclosed
US-12544374-B2 AZA-quinoline compounds and uses thereof NOVARTIS AG (CH) 2026-02-10 US disclosed
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 US disclosed
EP-4522608-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2025-03-19 EP disclosed
EP-4467199-A2 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2024-11-27 EP disclosed
CN-118908957-A Small molecule inhibitors of NF- κB induced kinase 詹森药业有限公司 2024-11-08 CN disclosed
CN-114746414-B Aza-quinoline compounds and uses thereof 诺华公司 2024-10-18 CN disclosed
EP-3976597-B1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-08-28 EP disclosed
EP-4034535-A1 AZA-QUINOLINE COMPOUNDS AND USES THEREOF Novartis AG (CH) 2022-08-03 EP disclosed
CN-114746414-A Aza-quinoline compounds and uses thereof 诺华公司 2022-07-12 CN disclosed
EP-3976597-A1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE Janssen Pharmaceutica NV (BE) 2022-04-06 EP disclosed
CN-114222737-A Small molecule inhibitor of NF-kB induced kinase 詹森药业有限公司 2022-03-22 CN disclosed
US-11254673-B2 Small molecule inhibitors of NF-κB inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2022-02-22 US disclosed
US-20210300918-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 US disclosed
WO-2021057853-A1 AZA-QUINOLINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2021-04-01 WO disclosed
WO-2021057853-A1 AZA-QUINOLINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2021-04-01 WO disclosed
WO-2020239999-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2020-12-03 WO disclosed
CN-105658639-A Alkynyl alcohols and methods of use 豪夫迈·罗氏有限公司 2016-06-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300918-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB POLB 996/4885IKBKB 2/4885SYK 286/4885
US-20260076968-A1 AZA-QUINOLINE COMPOUNDS AND USES THEREOF EZH2, SUZ12, NR3C1 POLB 1430/4885IKBKB 2346/4885SYK 3244/4885
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB POLB 518/4885IKBKB 3/4885SYK 601/4885
US-12544374-B2 AZA-quinoline compounds and uses thereof EZH2, NR3C1, SUZ12 POLB 1924/4885IKBKB 1655/4885SYK 3060/4885
US-11254673-B2 Small molecule inhibitors of NF-κB inducing kinase NFKBIA, IKBKB, CHUK POLB 1935/4885IKBKB 2/4885SYK 284/4885
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase IRAK3, IKBKB, IKBKG POLB 2829/4885IKBKB 2/4885SYK 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.